Eli Lilly reported a strong second quarter for 2026, easily surpassing Wall Street expectations as demand for its primary weight loss and diabetes treatments continues to rise. The company announced that revenue reached 22.97 billion dollars, which comfortably beat analyst predictions. This performance was driven by significant adoption of both Zepbound and Mounjaro across global markets.
Following these results, the pharmaceutical giant increased its full-year sales outlook. Eli Lilly now projects revenue between 85 billion and 87 billion dollars, up from previous forecasts. The company is currently capitalizing on its position in the obesity and diabetes market, where it maintains a 60.9 percent share in the United States.
Management also highlighted the early success of its new obesity pill, Foundayo, which launched in April. With prescription rates for the drug doubling in a single month, the firm sees oral medication as a clear growth opportunity. This momentum persists despite downward pressure on realized drug prices in the U.S. and abroad.
To support long-term growth, the company is using this cash flow to acquire smaller firms, including recent deals in the vaccine and psychedelics sectors. CEO Dave Ricks noted that the company is in a favorable position as it moves through the remainder of the year. The firm expects to see continued benefits from expanding Medicare coverage for obesity treatments, which recently began providing access for eligible seniors.